Clinical trials have been conducted with exemestane up to 800 mg as a single dose in healthy female volunteers and up to 600 mg daily in postmenopausal women with advanced breast cancer; these dosages were well tolerated. The single dose of exemestane that could result in life-threatening symptoms is not known. In rats and dogs, lethality was observed after single oral doses equivalent respectively to 2,000 and 4,000 times the recommended human dose on a mg/m2 basis. There is no specific antidote to overdose and treatment must be symptomatic. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.